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Abstract 
Rationale: Steroid receptor activator (SRA), a long non-coding RNA, serves as a critical regulator 
of gynecologic cancer. The objective of this study was to determine biological function and clinical 
significance of SRA expression in endometrial cancer.  
Method: We investigated whether SRA was involved in the development of endometrial cancer via 
binding to eukaryotic translation initiation factor 4E-binding protein 1 (EIF4E-BP1) as a transcription 
factor to enhance Wnt/ β-catenin signaling pathway.  
Results: Expression levels of SRA were upregulated in endometrial cancer tissues compared to 
those in adjacent control tissues. We also found high expression of SRA in EC cells. The relationship 
between SRA and EIF4E-BP1 was corroborated by transfection of a luciferase reporter plasmid. In 
addition, SRA knockdown inhibited the expression of EIF4E-BP1 known to play a critical role in the 
control of protein synthesis, cell growth, and cell survival, thus promoting tumourigenesis and 
epithelial-mesenchymal transition (EMT) important for cell motility and metastasis. Consistently, 
immunostaining and western blotting analysis showed that expression levels of β-catenin and 4EBP1 
in the nucleus were significantly decreased by SRA knockdown but increased by SRA 
over-expression.  
Conclusions: These results suggest that SRA is involved in proliferation, migration, and invasion of 
endometrial cancer cells by increasing the expression of EIF4E-BP1 and activity of Wnt/ β-catenin 
signaling. These findings indicate that SRA might be a novel biomarker for predicting recurrence and 
prognosis. It might also serve as a promising therapeutic target in endometrial cancer. 
Key words: Endometrial cancer (EC), Steroid Receptor Activator (SRA), Signaling pathway, Eukaryotic 
translation initiation factor 4E-binding protein 1 (EIF4E-BP1), Wnt/ β-catenin signaling 
Introduction 
Endometrial cancer (EC) is one of the most 
common gynecologic cancer. The incidence of EC has 
remarkable increased in recent years. EC rarely occurs 
in women before the age of 40 years or after the age of 
70 years. Its prognosis is poor. The 5-year survival rate 
of endometritis with appropriate treatment is 80%. [1] 
The recurrence rate of uterine hysterectomy in early 
stage is 3~17% depending on whether primary 
treatment or adjuvant therapy is performed. Most 
cases of recurrence occur after 2 to 3 years of 
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treatment (64% after 2 years and 87% after 3 years). [2] 
Thus, recent research has focused on finding 
tumor-specific markers that can predict the biological 
behavior of EC in relation to cellular motility and 
invasion. [3] However, pathological features and 
prognosis of patients with EC remain controversial. 
Recent studies have shown that non-coding RNA may 
be involved in the development of EC. [4, 5]  
Non-coding RNAs (ncRNAs) is a key component 
that can influence gene regulation and cancer cell 
phenotypes. [6, 7] Increasing number of studies have 
confirmed the presence of lncRNA in the cytoplasm 
and found that lncRNA is also involved in translation 
and post-translational regulation of gene expression. 
[8, 9] LncRNA transcription is highly regulated. [10, 
11] In addition, lncRNA may contain various types of 
binding domains to allowing binding with effector 
and repressor molecules as well as binding of protein 
complexes to larger functional units. [7, 12] Recently, 
it has been shown that lncRNA plays a role in 
biological events such as cell growth and 
differentiation.  
The steroid receptor RNA activator (SRA) was 
identified as functional RNA transcript existing in a 
ribonucleoprotein complex. That can co-activate 
steroid nuclear receptors. SRA was located on human 
chromosome 5q31.3 containing 5 exons and 4 introns. 
SRA was approximately 0.87 kB in size. SRA is both a 
protein-coding and non-coding RNA. [13-15] 
LncRNA SRA with an important function in tumor. It 
functions as a molecular coactivator for the expression 
of genes encoding SRA such as progesterone and 
estrogen in the development of cancer. It has been 
shown that SRA can activate hormone receptors that 
are associated with gynecologic cancers such as 
ovarian cancer and breast cancer. LncRNA SRA has 
been implicated in normal biological processes such 
as apoptosis, lipogenesis, steroidogenesis, muscle 
formation, and insulin signaling. It has also been 
shown to play a role in breast cancer, prostate cancer, 
abnormal cardiac development, and fertility 
reduction. [16, 17] In addition, lncRNA SRA has been 
studied in relation to tumor progression, although the 
mechanism is insufficient. To elucidate lncRNA SRA 
mechanism through EIF4E-PB1, which is known to be 
a downstream target for this cell growth and 
proliferation. 
Eukaryotic translation initiation factor 
4E-binding protein 1 (EIF4E-BP1) belongs to a family 
of translation-repressor proteins. It is one of two main 
downstream effectors of mammalian target of 
rapamycin (mTOR). [18, 19] EIF4E-BP1 is known to 
have important effect on mTOR signaling through 
translational control of key carcinogenic mRNA 
encoding proteins for cell cycle progression, cell 
survival, angiogenesis, cancer progression and 
metastasis. EIF4E-BP1 expression is regulated by 
transcriptional and post-translational mechanisms. 
[20-22] EIF4E-BP1 is an oncogene that is 
overexpressed in a wide range of cancers. [23]  
 Accordingly, in this study, we investigated 
expression levels of SRA in EC patient tissues and 
analyzed the relationship among SRA expression, 
clinicopathological findings, and disease prognosis. 
Functional analysis was also performed to examine 
effects of SRA on invasion and migration of EC cells 
both in vitro and in vivo. Finally, we examined 
whether SRA was involved in the development of EC 
cells via EIF4E-BP1 mediated Wnt/ β-catenin 
regulation.  
Materials and Methods 
Tissue collection 
 All experiments were performed with approval 
from the review board for human research of Yonsei 
University Hospital. Tissue samples of endometrial 
patients were collected at the time of surgery. These 
samples were immediately snap-frozen in liquid 
nitrogen and kept at –80℃ until RNA extraction.  
Cell culture 
 ECC-1 and Ishikawa EC cell lines were 
purchased from Sigma-Aldrich and ATCC. These cell 
lines were maintained in Minimum Essential Medium 
(MEM; Welgene Inc., Daegu, Korea) and RPMI-1640 
(Welgene Inc) at 37℃ in an atmosphere of 5% CO2. 
Culture medium was replaced with fresh medium 
every 2-3 days. 
Transfection of siRNAs 
 siRNAs (SRA and negative control (siNC)) were 
purchased from Genolution (Genolution 
Phamaceutical Inc, Seoul, Korea). Cells were added to 
6-well plates at density of 5×104 cells/well. To 
transfect these cells with 10 nM siRNA in 
phosphate-buffered saline (PBS), a G-Fectin Kit 
(Genolution Phamaceutical Inc) was used according 
to the manufacturer’s instructions. At 48 h post 
transfection, siRNA transfected cells were used for in 
vitro assay. Target siRNA sequences were listed in 
Supplementary Table 1, 2.  
Plasmid constructs and generation of stable 
cell lines 
 PCR was used to amplify human SRA transcript 
variant 3 cDNA. It was then inserted into a 
pLenti6/V-5-TOPO vector (ViraPower™ Lentiviral 
Expression Systems, Invitrogen, Carlsbad, CA, USA). 
The plasmid was then transfected into 293FT cell line 
for packaging. The resultant lentivirus was used to 
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infect cell lines. Medium containing blasticidin 
(Invitrogen, Karlsruhe, Germany) was used for 
selecting SRA stably transfected cells. Plasmid 
pLKO.1-puro (control TRC shRNA vector) was used 
to transfect ECC-1 and Ishikawa cells. Cells 
transfected with the pLKO.1-puro plasmid were 
selected with 4 μg/ml puromycin and stable clones 
were maintained with 1 μg/ml puromycin. Three 
stable clones were isolated. Transfection was 
performed using Lipofectamine 2000 (Invitrogen) 
following the manufacturer’s instructions.  
 
Table 1. Association between SRA expression and 
clinicopathologic factors in endometrial cancer (n=146). 
  SRA expression  
 n (%) Low High P-valuea 
Age 
(mean±SD) 
146 52.49±7.41 51.99±9.93 0.749 
Stage    0.001 
Ι 101 47 54  
Ⅱ 13 1 12  
Ⅲ 19 3 17  
Ⅳ 13 3 10  
Grade    0.258 
Ι 75 32 43  
Ⅱ 57 17 40  
Ⅲ 14 4 10  
BMI    0.185 
<18.5 6 1 5  
18.5_25 74 33 41  
>25_30 55 16 39  
>30 11 3 8  
Tumor size   0.413 
<2cm 60 26 34  
2-3.9cm 35 11 24  
4-5.9cm 15 6 9  
≥6cm 36 10 26  
Menopause   0.715 
No 44 15 29  
Yes 102 38 64  
Lymphatic metastasis  0.025 
No 129 51 78  
Yes 17 2 15  
aChi-square test or Fisher’s exact test were used to calculate P-values. 
 
Table 2. Univariate and multivariate analysis of various factors for 
overall survival. 
  Overall Survival 
  Univariate analysis Multivariate analysis 
  HR (95% CI) P HR (95% CI) P 
SRA expression 11.114 
(1.481-83.412) 
0.003 10.218 
(1.340-77.916) 
0.025 
Age, years 
(continuous) 
1.102 (1.051-1.156) 0.0001 1.107 (1.042-1.175) 0.001 
FIGO stage 2.171 (1.499-3.143) 0.000004 1.507 (0.948-2.395) 0.083 
Grade 3.066 (1.611-5.834) 0.0003 2.480 (1.137-5.409) 0.022 
Lymph node 
metastasis 
3.009 (1.081-8.375) 0.027 0.937 (0.251-3.494) 0.922 
BMI 0.806 (0.404-1.604) 0.538   
Menopause 3.494 
(0.807-15.138) 
0.074   
tumor size 1.521 (1.058-2.186) 0.018 0.955 (0.628-1.452) 0.83 
 
 
Quantitative real-time PCR analysis (qPCR) 
 RNAs were extracted from samples and cell 
lines (TRIzol® reagent, Invitrogen). For 
reverse-transcription of 2 µg total RNA into 
first-strand cDNA, a reverse transcription kit 
(Invitrogen) was used according to the 
manufacturer’s instructions. qRT-PCR was performed 
using SYBR® Green real-time PCR kit (Mbiotech, 
Seoul, Korea) in a 20 µl reaction volume on an ABI 
StepOnePlus Real-Time PCR system (Applied 
Biosystems, Foster City, CA, USA). β-actin was used 
as internal standard to normalize gene expression 
levels. The 2-∆∆CT method was used to analyze relative 
gene expression. Each qRT-PCR experiment was 
replicated ≥ 3 times. Results are expressed as extent of 
change relative to control values. Primers used for 
PCR reactions are listed in Supplementary Table 3.  
Luciferase reporter assay 
NCBI (http://www.ncbi.nlm.nih.gov) online 
database was used to predict potential transcription 
factor binding sites at EIF4E-BP1 promoter regions. 
Several SP1 binding motifs were identified. The 
EIF4E-BP1 promoter region (651 bp) was then 
synthesized and inserted into a pGL4-basic vector 
(Promega, Madison, WI, USA). Successful integration 
of this sequence into the vector was verified by 
sequencing. A Dual-Luciferase Assay Kit (Promega 
Inc) was used to assess luciferase activities following 
manufacturer’s protocol.  
Western blot analysis 
 Cells were lysed in 500 µl RIPA buffer (150 mM 
sodium chloride, 1% NP 40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM 
Tris-HCl [pH 8.0], 100 mM PMSF) and centrifuged at 
14,000 g for 15 min at 4℃. The supernatant was mixed 
with denaturing sample buffer (1:1) and boiled at 95℃ 
for 5 min. Equal amounts of protein (30 μg) were 
loaded and separated by 10% SDS-polyacrylamide gel 
electrophoresis and blotted onto PDVF membranes 
(Sigma-Aldrich, St Louis, MO, USA). These 
membranes were blocked with 5% non-fat dry milk in 
Tris-buffered saline containing 0.05% Tween 20 
(TBST) for 1 h at 4℃ and incubated with 
anti-β-catenin (1:1000), anti-VEGF (1:1000), anti-BCL-2 
(1:500), anti-Bax (1:1000), anti-APAF-1 (1:1000), 
anti-Caspase-9 (1:500), anti-Caspase-3 (1:1000), 
anti-PARF (1:1000), anti-E-cadherin (1:500), 
anti-N-cadherin (1:500), anti-Vimentin (1:1000), 
anti-Snail (1:1000), anti-Lamin B (1:1000) (all from Cell 
Signalling Technologies, Danvers, MA, USA), 
anti-EIF4E-BP1 (1:1000), anti-phospho-EIF4E-BP1 
(1:1000), anti-Wnt5β (1:1000), and anti-Twist (1:1000) 
(all from Abcam, Cambridge, MA) antibodies 
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overnight at 4℃. Anti-β-actin antibody (1:5000; 
Sigma-Aldrich) was used as an internal control. 
Membranes were washed with TBST and incubated 
with horseradish peroxidase-conjugated secondary 
antibodies (Jackson Immunoresearch, West Grove, 
PA, USA) for 1 h at room temperature. After washing 
again with TBST, signal was detected using an 
enhanced chemiluminescence kit (Thermo Scientific, 
Rockford, IL, USA) and intensity was quantified using 
ImageJ software.  
Matrigel Invasion and wound healing assays 
 Matrigel invasion assay was performed using 
BD Biocoat Matrigel Invasion Chamber (pore size, 8 
µm; 24 well; BD Biosciences, Bedford, MA, USA) 
according to the manufacturer’s instructions. Briefly, 
overexpression cells, shEIF4E-BP1 or siSRA 
transfected cells, and siNC-transfected cells (5×104 
cells/mL) were plated into the upper chamber in 
serum-free medium while complete medium was 
added to the bottom chamber. After 48 h of 
incubation, cells that had invaded through the 
membrane were stained using a Differential Quik 
Stain kit (Diff Quik, Sysmex, Kobe, Japan). The assay 
was performed in triplicate.  
 Cell migration was assessed using monolayer 
wound healing assay. Briefly, cells were seeded into 
6-well culture plates with serum-containing medium 
and allowed to grow to 90% confluency. The 
serum-containing medium was then removed, after 
which cells were serum starved for 24 h. When cell 
confluence reached nearly 100%, an artificial 
homogenous wound was created by scratching the 
monolayer with serum-free medium. Images of cells 
migrating into the wound were captured at 0, 24, and 
48 h using a microscope. Each experiment was 
repeated three times.  
Cell viability assay 
 An equal number of cells (1×104) transfected 
with siRNA, knocked down for EIF4E-BP1, and 
over-expressed with SRA were seeded into 96-well 
plates and incubated for 0 h, 24 h, 48 h, 72 h, and 96 h. 
The number of viable cells was determined using a 
Cell Counting Kit (CCK-8; Dojindo, Kumamoto, 
Japan). CCK-8 reagents were added to cultures and 
incubated for 4 h. The absorbance of each well was 
measured at wavelength of 450 nm with a 
micro-ELISA reader (Molecular Devices; Sunnyvale, 
CA, USA).  
Colony formation assay 
ECC-1 and Ishikawa cells were seeded (50000 
cells/well) in 6 well plates and incubated at 37℃ 
overnight. The following day, cells were incubated 
with siRNA, shRNA, or over-expression SRA. The 
culture medium was changed every week for another 
2 weeks. Then, cells were washed twice with PBS, 
fixed with cold methanol for 30 min at 4℃ and stained 
with crystal violet dye (0.1% w/v) at room 
temperature for 1h. The plates were washed with 
water, dried and scanned.  
Flow cytometric analysis of apoptosis 
 For cell death analysis, after exponentially 
growing ECC-1 and Ishikawa cells were transfected 
with indicated plasmids for 48h, they were quantified 
by flow cytometry. Experiments were conducted 
using Annexin V-FITC Apoptosis Detection Kit (BD 
Pharmingen, San Diego, CA, USA) according to the 
manufacturer’s instruction. Apoptosis was then 
analyzed by flow cytometry. Cells were sorted using a 
FACS LSR II (BD Biosciences) and analyzed with BD 
FACSDiva software version 6.2. Apoptotic cells were 
calculated after FACS analysis. The analysis was 
performed in triplicate.  
Immunofluorescence  
ECC-1 cells were seeded onto glass coverslips in 
24-well plates. The next day, cells were cultured in 
serum-free medium for 24 h and transfected with 
siSRA or SRA for overexpression for 48 h. Cells were 
fixed with cold methanol for 15 min and blocked with 
5% normal rabbit serum and 0.4% Triton X-100 in PBS 
for 1 h. These cells were then incubated with primary 
antibodies of β-catenin (Cell Signaling, 1:500) at 4°C 
overnight. Cells were then mounted using 
Vectashield hardset mounting medium with DAPI 
(Vector Laboratories, Burlingame, CA, USA). 
Photomicrographs were captured using a Confocal 
microscope (LMS700).  
Xenograft in mice 
 BALB/c nude mice (n = 10, 4-5 weeks of age, 
Orient Bio, Seongnam, Korea) were kept in aseptic 
conditions with constant temperature and humidity 
(Yonsei Medical University protocol). Each mouse 
received a subcutaneous injection of a 100 µL 
suspension of ECC-1 cells into the dorsal scapula area. 
Calipers were used to measure tumor size one time 
per 5 days. Tumor volume was calculated using a 
simplified equation to estimate a rotational ellipsoid 
(length × width2 × 0.5). Each tumor was harvested at 
65 days post treatment. 
Magnetic resonance (MR) imaging and Micro 
PET imaging in mice 
 A Bruker Biospec 94/24 USR (9.4T) small animal 
scanner (35-mm diameter birdcage coil, Bruker 
BioSpin MRI, Ettlingen, Germany) was used to obtain 
MR images. T2-weighted images were obtained using 
rapid acquisition setting. They were acquired at the 
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beginning inside the magnet bore. A 1.5% isoflurane 
and O2/N2O (1:1) mixture at flow rate of 0.7 L/min 
was used for anesthesia during MR experiment.  
[18F]-fluorodeoxy-glucose (FDG) image was 
acquired as a reference to evaluate the agent as a 
diagnostic and therapy follow-up tracer. The same 
mouse was then injected with a 124I-la-beled derivative 
of pyropheophorbide-a, an imaging and 
photodynamic therapy bifunctional agent. Because of 
the long half-life of 124I (4.2 days), a longitudinal study 
(multiple scans over time) was possible with the same 
mouse and the same agent. Tumor uptake relative to 
the rest of the body increased over time, indicating 
that the agent had promising potential as both a 
therapeutic and a tumor-monitoring agent. After 
incubation with FDG, endometrial tumors were 
imaged using a microPET scanner (Inveon™ 
Dedicated PET, Siemens). PET image analyses were 
then performed using a standard software (Inveon™ 
Acquistion workplace).  
Hematoxylin and eosin (H&E) staining 
 Mouse were sacrificed. Tumor tissues were 
collected, fixed in 4% paraformaldehyde for 24 h, 
washed in PBS, and then embedded in paraffin. 
Two-micrometer sections were stained with 
hematoxylin and eosin following standard 
procedures.  
Statistical analysis 
 Results are expressed as mean ± standard 
deviation (SD) or mean ± standard error of mean 
(SEM). All statistical analyses were performed using 
SPSS standard version 20.0 (IBM, Chicago, IL, USA). 
Pearson’s χ2 test, Student’s t-test, and Fisher’s exact 
test were used to evaluate associations of SRA with 
clinicopathological characteristics. The Kaplan-Meier 
method was used to analyze overall survival time. 
Log-rank test was used to estimate differences 
between groups. Stepwise Cox regression model was 
used for multivariate survival analysis of parameters 
that were significant in univariate analysis. All tests 
were two-sided and a P value < 0.05 was considered 
to indicate statistically significant result.  
Ethics approval and consent to participate 
This study was approved by the Ethics 
Committee of Yonsei Severance Hospital, and 
informed consent was obtained from all patients. 
Samples were collected from 146 endometrial cancer 
patients who underwent surgery and a control group 
of 57 patients with benign gynecologic disease 
between Sep 2012 and Dec 2014. 
Results 
Expression of SRA is Upregulated in EC Tissues 
 Expression levels of SRA in 146 EC patient 
tissues and 57 corresponding normal endometrial 
tissues were determined by real time-PCR and 
normalized to β-actin. SRA expression in EC tissue 
was more than 2.9-fold higher than that in 
non-cancerous tissue (p < 0.05) (Figure 1A). 
Clinicopathologic factors and patient survival were 
compared between high (n = 92) and low SRA 
expression groups (n = 54) (Figure 1B). 
Clinicopathological data such as age, stage, histologic 
grade, BMI, tumor size, menopause, and lymph node 
metastasis were compared between high and low SRA 
expression groups (Table 1). High grade histology, 
tumor size, and lymph node metastasis were more 
frequently found in the high SRA expression group (p 
< 0.05). With regard to overall survival, patients with 
high SRA expression had significantly poorer 
prognosis than those with low SRA expression (Figure 
1C). Furthermore, receiver operating characteristic 
curve analysis showed that SRA level was useful for 
predicting survival of EC patients (area under the 
curve: 0.716; 95% confidence interval [CI]: 0.645 to 
0.786) (Figure 1D). Univariate analysis of overall 
survival revealed that the relative level of SRA 
expression, age, histologic grade, tumor size, 
menopause, and lymph node metastasis were 
prognostic indicators (Table 2). Variables with a value 
of p < 0.05 were selected for multivariate analysis. 
Multivariate analysis showed that SRA expression, 
age, and grade were independent prognostic 
indicators for overall survival in patients with EC 
(Table 2). 
SRA knockdown decreases proliferation, 
migration, and invasion of EC cells 
To investigate the role of SRA in EC cell lines, 
ECC-1 cells and Ishikawa cells were examined for 
SRA expression. Results showed that ECC-1 cells and 
Ishikawa cells expressed higher levels of SRA than 
control cells (HaCaT) (Figure 2A). Knockdown 
efficiency of SRA specific siRNAs (siSRA) was 
analyzed by qRT-PCR. Results revealed that siSRA 
had higher silencing efficiency compared to control 
(siNC) (Figure 2B). The proliferation of 
siSRA-transfected EC cells and siNC was measured 
by CCK-8 assay. At 96 h post-transfection, 
knockdown of SRA inhibited cell proliferation by 55% 
and 10% in ECC-1 and Ishikawa cells, respectively, 
relative to control (siNC) (Figure 2C). In addition, 
knockdown of SRA inhibited colony formation in 
ECC-1 and Ishikawa cells (Figure 2D). Effects of SRA 
on invasion and migration of EC cells were assessed 
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by wound healing assays and Matrigel invasion, 
respectively. Wound healing assays showed larger 
width of wound in siSRA-transfected ECC-1 and 
Ishikawa cells than that in siNC-transfected cells, 
demonstrating decreased migration of EC cells via 
down-regulation of SRA (Figure 2E). According to 
Matrigel invasion assay, knockdown of SRA 
significantly reduced the number of invasive cells by 
more than 53% in ECC-1 cells (Figure 2F). We 
repeated with another siRNA to a different region of 
the transcript to minimize the possibility of off-target 
effects. The most efficient siSRA1 was selected and 
used for the experiment (Supplementary Figure 1). 
Overexpression of SRA promotes proliferation, 
migration, and invasion of EC cells 
 Lentiviral-mediated overexpression of SRA was 
performed to determine the functional role of this 
lncRNA in ECC-1 cells. qRT-PCR analysis showed 
that SRA was successfully overexpressed in ECC-1 
cells compared to that in control cells (p < 0.001) 
(Figure 3A). We next examined the impact of SRA 
overexpression on cell proliferation. Results of CCK-8 
assays showed that overexpression SRA in ECC-1 
cells increased cell proliferation (Figure 3B), 
suggesting that SRA was involved in the proliferation 
of EC cells. Thereafter, Colony formation assays 
confirmed that SRA overexpression promoted cell 
colony formation (Figure 3C). Effects of SRA on 
invasive and migratory behaviors of cells were 
assessed by wound healing assays and Matrigel 
invasion, respectively. Overexpression of SRA 
resulted in increased migration of ECC-1 cells relative 
to empty vector-expressing controls (Figure 3D). 
There was a significant difference between scratch 
width percentages of each cell line at 24 and 48 h after 
scratching. Empty vector and SRA overexpression 
groups of ECC-1 cells were significantly different in 
scratch width (Figure 3E). Furthermore, SRA 
overexpression in ECC-1 cells significantly increased 
invasion relative to that in empty vector-expressing 
cells. Relative percentages of invaded cells of ECC-1 at 
48h after incubation in empty vector and SRA 
overexpression groups were significantly different 
(Figure 3F). Taken together, these results indicate that 
overexpression of SRA can promote invasion and 
migration of ECC-1 cells in vitro.  
 
 
Figure 1. SRA expression in human endometrial cancer patient tissues. (A) Relative expression of SRA was significantly higher in endometrial cancer (EC) 
patient tissues (n=146) than that in noncancerous patient tissues (n=57). SRA expression was determined using quantitative real time polymerase chain reaction with 
β-actin as an internal control. (B) SRA expression was classified into two groups according to the expression level of EC tissues. (C) Relative SRA expression and its 
clinical significance based on Kaplan-Meier overall survival curves of patients with endometrial cancer and different levels of SRA. (D) Receiver operating characteristic 
(ROC) curve for prognosis prediction of patients using SRA level. The area under curve (AUC) is shown in plots. Data are expressed as mean ± standard deviation. 
*p<0.05 vs. non-tumor control. 
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Effect of lncRNA SRA on Wnt/ β-catenin 
signaling pathway 
Previous studies have suggested that SRA is 
involved in cell proliferation, invasion, migration, and 
metastasis. [24] However, the mechanism through 
which that SRA plays a role in EC has not been 
elucidated yet. The Wnt signaling pathway regulates 
various developmental processes such as cell 
migration, attachment, proliferation, and cell death. In 
the present study, we tried to confirm the functional 
relationship between Wnts and EC. We evaluated 
expression levels of β-catenin, Gsk-3β, and h-cMyc. 
Results showed that β-catenin and h-cMyc expression 
levels were decreased whereas Gsk-3 β levels were 
increased in the group transfected by siSRA compared 
to those in the group transfected by siNC (Figure 4A). 
Moreover, β-catenin and h-cMyc expression levels 
were increased whereas Gsk-3 β levels were 
decreased by overexpression of SRA compared with 
those in the control transfected with an empty vector) 
(Figure 4B). We also evaluated protein levels of 
β-catenin. Results showed that its expression was 
markedly decreased in the group transfected with 
siSRA (compared to that in the group transfected with 
siNC) but increased in the group overexpressed with 
SRA (compared to that in the group transfected with 
an empty vector) (Figure 4C, 4D). Next, we used cell 
fractionation method to examine β-catenin 
distribution in the nucleus and cytoplasm. We found 
that cytoplasmic β-catenin was substantially 
increased in SRA-silenced ECC-1 cells compared to 
that in control cells transfected with siNC. On the 
contrary, the reserve result was observed for nuclear 
β-catenin (Figure 4E). In addition, we also found that 
cytoplasmic β-catenin was substantially decreased in 
SRA over-expressed ECC-1 cells compared to that in 
control cells transfected with an empty vector. The 
reverse result was observed for nuclear β-catenin 
(Figure 4F). Taken together, these data suggest that 
gene silencing of SRA can inactivate the Wnt/ 
β-catenin signaling pathway.  
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Figure 2. Knockdown of SRA inhibits endometrial cancer cell proliferation, migration, and invasion. (A) Expression of SRA in human keratinocyte 
(HaCaT) and human endometrial cancer cell lines determined by quantitative real time polymerase chain reaction (qRT-PCR). (B) Knockdown efficiency was 
determined by qRT-PCR analysis in ECC-1. Cells were transfected with SRA siRNA (siSRA) or negative control siRNA (siNC). (C) Knockdown of SRA decreases cell 
proliferation in ECC-1 and Ishikawa cells. The proliferation of endometrial cancer cells transfected with siSRA and negative control siRNA (siNC) was determined 
using Cell Counting Kit-8 assays (siRNA: 10µM). (D) Knockdown of SRA inhibited colony formation in ECC-1 and Ishikawa cells. (E) Wound healing assay was used 
to determine migration in SRA-specific siRNA (siSRA)-transfected ECC-1 and Ishikawa cells (×200). (F) Matrigel invasion assay was used to determine invasion after 
48 h in siSRA transfected ECC-1 and Ishikawa cells. Bars indicate mean ± standard deviation of three independent experiments performed in triplicate. *p < 0.05, **p 
< 0.01, and ***p < 0.001 vs. siNC. 
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Figure 3. Overexpression of SRA inhibits endometrial cancer cell proliferation, migration, and invasion. (A) Overexpression of SRA in ECC-1 cells was 
analyzed using qRT-PCR. (B) Cell proliferation was analyzed using Cell Counting Kit-8 assays. (C) Overexpression of SRA promoted cell colony formation in ECC-1 
cells. (D) Wound healing assay observed under the optical microscope was used to determine migration in SRA-overexpressing ECC-1 cells (×200). Cells after 24 and 
48 h of incubation were analyzed and determined using ECC-1 cells as control. (E) Wound healing assay results showing percentage of each cell line. (F) Cell invasion 
observed under an optical microscope. Matrigel invasion assays were used to determine invasion after 48 h of incubation of SRA-overexpressing ECC-1 cells. (G) 
Matrigel invasion assay results showing percentage of each cell line. Bars indicate mean ± standard deviation of three independent experiments performed in triplicate. 
*p < 0.05, **p < 0.01, and ***p < 0.001 vs. ECC-1, Vector cells.  
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Figure 4. Wnt/β-catenin pathway mediates oncogenic activity of SRA in ECC-1 cells. (A) Expression levels of β-catenin, Gsk-3β, and h-cMyc mRNAs 
were measured in ECC-1 cells transfected with siSRA or siNC. (B) Expression levels of β-catenin, Gsk-3β, and h-cMyc mRNAs were measured in SRA over-expressing 
ECC-1 cells. Bars indicate mean ± standard deviation of three independent experiments performed in triplicate. *p < 0.05 vs. siNC. (C) Cytoplasmic and nuclear 
β-catenin levels in SRA knockdown ECC-1 cells were measured. (D) Cytoplasmic and nuclear β-catenin levels in SRA over-expressing ECC-1 cells were measured. (E, 
F) Subcellular β-catenin localization in indicated cells was assessed by immunofluorescence staining. Immunofluorescence staining of β-catenin (green) showed nuclear 
and cytoplasmic localization in cells transfected with siNC, siSRA, empty vector (control), or SRA over-expression. Nuclei were counterstained with DAPI (blue). 
Total magnification was 200×. Images were zoomed in 500%. 
 
SRA interacts with EIF4EBP1 
To validate the interaction between SRA and 
EIF4E-BP1, luciferase assays were carried out. We 
constructed luciferase reporter plasmids for 
EIF4E-BP1 containing predicted wild-type and 
mutant-binding sites for EIF4E-BP1 (Figure 5A). We 
found that downregulation of SRA reduced the 
luciferase activity of the wild-type plasmid but not 
that of the mutant plasmid. Co-transfection of the 
plasmid containing the wild-type UTR plus an 
EIF4E-BP1, but not a negative control, resulted in a 
significant increase in relative luciferase activity 
(Figure 5B). In contrast, co-transfection of the plasmid 
with the mutated UTR plus either mimic completely 
transfected siSRA repression, demonstrating the 
specificity of these siSRA for EIF4E-BP1 suppression. 
In addition, p-EIF4E-BP1, EIF4E-BP1, and VEGF 
expression levels were analyzed by western blotting. 
In ECC-1 cells, SRA knockdown and SRA 
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overexpression regulated EIF4E-BP1 expression 
typical of tumor progression. The same results were 
obtained for cells transfected with EIF4E-BP1 (Figure 
5C). Expression levels of phospho-EIF4E-BP1 and 
EIF4E-BP1 were increased in SRA-overexpressed cells 
but decreased in SRA knocked-down cells. Expression 
levels of phosphor-EIF4E-BP1 and EIF4E-BP1 were 
also decreased in cells transfected with shEIF4E-BP1. 
There was no significant difference in the expression 
of VEGF.  
Knockdown of EIF4E-BP1 suppresses 
proliferation, migration, invasion, and 
apoptosis of EC cells  
To further determine whether EIF4E-BP1 could 
regulate SRA expression, the expression of EIF4E-BP1 
was knocked down in ECC-1 and Ishikawa cells. We 
repeated with another siRNA to a different region of 
the transcript to minimize the possibility of off-target 
effects. (Supplementary Figure 2). After confirming 
the effects of siEIF4E-BP1, the EIF4E-BP1-shRNA cell 
line was used in the experiment. Knockdown of 
EIF4E-BP1 was performed by transfecting with 
EIF4E-BP1-shRNA. Viability, migration, invasion, and 
apoptosis of EC cells were then determined using 
CCK-8, wound healing assays, Matrigel invasion, and 
flow cytometry, respectively. We found that 
downregulation of EIF4E-BP1 notably inhibited cell 
viability (Figure 6A). In addition, downregulation of 
EIF4E-BP1 significantly inhibited colony formation in 
ECC-1 cells (Figure 6B). We further investigated the 
potential effect of EIF4E-BP1 on EC cell apoptosis. 
Results of flow cytometry analysis determined by 
Annexin V-FITC/PI double staining revealed that 
knockdown of EIF4EPB1 significantly induced 
apoptosis of ECC-1 and Ishikawa cells compared with 
the control (transfection with NC-shRNA) (Figure 
6C). Besides, downregulation of EIF4E-BP1 notably 
elevated levels of BCL-2, Bax, APAF-1, cleaved 
Caspase 3/9, and PARP in EC cells (Figure 6D). We 
further investigated whether EIF4E-BP1 could affect 
the migration and invasion of EC cells. Wound 
healing assay showed that the migration ability was 
significantly decreased in the EIF4E-BP1-shRNA 
group compared to that in the NC-shRNA group both 
in ECC-1 and Ishikawa cells (Figure 6E). The result of 
Matrigel invasion assay revealed that knockdown of 
EIF4E-BP1 remarkably reduced the number of 
invasive cells (Figure 6F).  
 
 
Figure 5. Luciferase assay of EIF4E-BP1 promoter activity in ECC-1 cells. (A) The negative pGLO.4 insert indicates an empty sequence. Data are presented 
after normalizing transfection efficiency using Renilla luciferase reporter gene. (B) ECC-1 cells were co-transfected with indicated luciferase reporter plasmids, siNC, 
or siSRA-EIF4E-BP1. Luciferase activity was analyzed 24 h later. Bars indicate mean ± standard deviation of three independent experiments performed in triplicate. *p 
< 0.05 vs. promoter control. (C) p-EIF4E-BP1, EIF4E-BP1, and VEGF expression was analyzed by western blotting. 
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Figure 6. Knockdown of EIF4E-BP1 decreased the proliferation and apoptosis of endometrial cancer cells. (A) Viability of ECC-1 and Ishikawa cells 
transfected with NC-shRNA or EIF4E-BP1 based on CCK-8 assay. (B) Down-regulation of EIF4E-PB1 inhibited cell colony formation in ECC-1 cells. (C) Apoptosis of 
ECC-1 and Ishikawa cells was detected by flow cytometry. (D) Western blot was used to assay protein levels of BCL-2, Bax, APAF-1, cleaved Caspase 3/9, and PARP 
in endometrial cancer cells transfected with NC-shRNA or EIF4E-BP1-shRNA. (E) Wound healing assay for the migration of ECC-1 and Ishikawa cells transfected with 
NC-shRNA or EIF4E-BP1-shRNA. (F) Matrigel invasion assay for the invasion of ECC-1 and Ishikawa cells. Bars indicate mean ± standard deviation of three 
independent experiments performed in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. control or NC-shRNA. 
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Overexpression of SRA in ECC-1 cells increases 
xenograft tumor growth in vivo 
 In vitro studies showed that overexpression of 
SRA promoted EC cells proliferation, invasion, and 
migration. To further determine whether SRA 
expression could enhance the tumorigenicity of EC 
ECC-1 cells in vivo, we inoculated ECC-1 cells as 
xenografts into nude mice (Figure 7A). Tumor volume 
and weight were measured. Mean tumor volumes and 
weights (2752.214 ± 326.1 mm3 and 1,760 ± 20 mg, 
respectively) at day 65 in mice receiving 
SRA-overexpressing ECC-1 cells were significantly 
larger than those (1409.166 ± 260.1 mm3 and 542 ± 16 
mg, respectively) in mice receiving empty 
vector-expressing cells (p < 0.05) (Figure 7B). SRA 
expression in tumor tissue was significantly greater in 
SRA-overexpressing cells compared to that in control 
cells (Figure 7C, 7D). Tumor weight was correlated 
with tumor volume as determined by microscale (p < 
0.05). Histological examination revealed that more 
cells with large nucleoli and irregular nuclear 
membranes were present in SRA-overexpressing 
xenografts than those in control xenografts (Figure 
7E). We further evaluated tumor size and activity 
using magnetic resonance imaging (MRI) and 
positron emission tomograph (PET) (Figure 7F, 7G). 
Tumor growth was strongly induced by SRA 
overexpression. Tumor size and fluorodeoxyglucose 
(FDG) accumulation were significantly larger and 
greater, respectively, in mice inoculated with 
SRA-overexpressing cells. These findings suggest that 
SRA could promote tumor growth in vivo, further 
supporting our hypothesis that SRA is involved in the 
pathogenesis of malignant transformation of EC cells. 
Next, we determined expression levels of Wnt/ 
β-catenin related proteins in xenografts derived from 
SRA-overexpressing ECC-1 cells. E-cadherin, 
N-cadherin, β-catenin, Vimentin, Wnt-5β, Twist, 
Snail, and EIF4E-BP1 protein levels were greater in 
SRA-overexpressing tumor than those in control 
tumors (Figure 7H).  
Discussion 
Recently, lncRNA has become the focus of 
intensive research because it plays an important role 
in malignant processes including tumor formation, 
drug resistance, and metastasis. [25, 26] LncRNA 
exhibits tissue-specific expression patterns. It has been 
functionally characterized. Biosynthesis of theses 
RNAs is important for a variety of physiological 
processes. Abnormal expression of lncRNA may 
affect cancer development and progression. [17] 
However, the molecular mechanism of lncRNA 
associated with tumor progression and metastasis has 
not been fully understood yet.  
Previous studies have examined molecular 
function and clinical significance of SRA expression in 
cervical cancer tissues and cell lines. Transitional 
effects of SRA appear to be mediated, at least in part, 
by regulation of genes involved in cell migration, 
invasion and EMT. [15, 24] However, little is known 
about the biological function of SRA in EC. Also, since 
molecular mechanisms of lncRNA associated with 
tumor progression and metastasis are not fully 
understood yet, questions have been raised as to 
whether SRA promotes metastasis of EC by 
modulating gene expression encoding proteins 
involved in metastasis. [27] A deeper understanding 
of the molecular mechanism underlying the 
progression and metastasis of EC is essential for the 
development of more effective therapies and for the 
identification of new diagnostic markers for EC.  
Most of previous studies were focused on SRA 
gene expression. In this study, the expression of SRA 
gene was increased in 63% of EC patients and 
correlated with FIGO stage and lymph node 
metastasis. High expression of the SRA gene was 
positively correlated with overall survival of EC. 
Furthermore, knockdown of SRA inhibited 
proliferation, invasion, and migration of EC cells. 
Conversely, overexpression of SRA increased 
proliferation, invasion, and migration of ECC-1 cells, 
suggesting that SRA could contribute to the 
invasiveness and mobility phenotype of EC cells. 
These observations are relevant to SRA because its 
upregulation is similarly associated with cancer cell 
growth and migration.  
 
Next, we investigated the mechanism of SRA by 
SRA target prediction. One possible mechanism is 
through Wnt signaling. It is known that Wnt family 
regulates a wide range of cellular functions, including 
cell growth, proliferation, polarity, differentiation, 
and development. [28, 29] As an important 
transcription factor, β-catenin acts as a major effector 
of the canonical Wnt signaling cascade. [30] As a 
result, we found that SRA regulates β-catenin, Gsk-3β, 
and h-cMyc involved in the activation of the Wnt/ 
β-catenin signaling pathway. In addition, we 
hypothesized that the expression of SRA could 
regulate the Wnt signaling pathway. Cytoplasmic 
β-catenin is degraded by multiple proteolytic 
complexes when the Wnt signaling pathway is 
inactive. Conversely, β-catenin avoids degradation 
and accumulates in the cytoplasm. It eventually 
translocates to the nucleus during Wnt signaling 
pathway activity and displays transcriptional activity. 
[31] As expected, the amount of β-catenin was 
significantly decreased in the nucleus after SRA 
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knockdown but increased in the nucleus after SRA 
overexpression. The Wnt/ β-catenin signaling 
pathway is known to regulate gene expression 
through cyclin D1 and c-Myc. [32] Eukaryotic 
translation initiation factor 4E-binding protein 1 
(EIF4E-BP1) mediates a tight regulation of expression 
of many proteins including cyclin D1, survivin, 
c-Myc, and vascular endothelial growth factor (VEGF) 
that are critical to cell division, cell growth, and 
angiogenesis. [33] 
 
 
Figure 7. Effect of SRA on tumor growth in vivo. (A) ECC-1 cells (5 × 106) stably expressing SRA were inoculated into nude mice and the effect of SRA on 
endometrial cancer growth was examined after 65 days (n=5). Photograph of tumors are presented. (B) Tumor volume was calculated every 5 days. Data are 
presented as mean ± SD (n=5). * p< 0.05 vs. control. (C) Tumor weight. Data are presented as mean ± SD. * p< 0.05 vs. control. (D) qRT-PCR analysis of SRA 
expression in tissues of resected tumors. Bars indicate mean ± standard deviation of three independent experiments performed in triplicate. **p < 0.01 vs. Control. 
(E) Haematoxylin and eosin (H&E) staining at 65 days after injection. (F) Micro PET image with transverse (a), coronal (b), and sagittal (c) plane slices of mice showing 
FDG uptake in the affected right carotid artery (arrows). (G) MRI imaging. (H) SRA overexpression promotes EMT, Wnt/β-catenin and mTOR-related expression in 
xenograft. E-cadherin, N-cadherin, β-catenin, Vimentin, Wnt-5β, Twist, Snail, and 4EBP1 expression levels were analyzed by western blotting.  
Int. J. Biol. Sci. 2020, Vol. 16 
 
 
http://www.ijbs.com 
114 
In case studies, EIF4E-BP1 alteration was 
strongly related to survival in ovarian cancer patients. 
[34] EIF4E-BP1 mediates phenotypic changes by 
selectively enhancing translation of restricted mRNA 
pools encoding proteins associated with malignant 
tumors. This enhanced EIF4E-BP1 can contribute to all 
aspects of malignant progression. [35] 
Post-transcriptional inhibition of EIF4E-BP1 mediated 
pathway in EC cells by SRA was demonstrated in this 
study. We found a direct interaction between SRA and 
EIF4E-BP1. Knockdown of SRA was associated with 
inhibition of luciferase activity under the control of 
EIF4E-BP1 3’-UTR. In addition, it has been 
demonstrated that SRA knockdown induces 
significant downregulation of EIF4E-BP1 mRNA and 
protein. Our results showed that EIF4E-BP1 was a 
direct target of SRA and that the reduction of SRA 
partially reduced EIF4E-BP1 expression as well as 
invasiveness and mobility. EIF4E-BP1 shRNA 
reduced cell proliferation and invasion in ECC-1 and 
Ishikawa cells. This indicates that this ability is 
EIF4E-BP1-denpendent.  
In conclusion, our study emphasizes the clinical 
validity of SRA in predicting the prognosis of EC. It 
provides homeostasis and interactions in the EC 
through the Wnt/ β-catenin signal. Further 
experiments revealed that EIF4E-BP1 was a direct and 
functional target of SRA in EC cells. Thus, SRA can be 
a diagnostic marker and therapeutic target in the 
treatment of EC. 
In summary, steroid receptor RNA activator 
(SRA) is a long non-coding RNA with an important 
function in tumor. It can activate human hormone 
receptors that are strongly associated with 
gynecologic cancers. In addition, SRA knockdown can 
inhibit the expression of EIF4E-BP1 that plays a 
critical role in the control of protein synthesis, cell 
growth, and cell survival, thus promoting 
tumorigenesis and epithelial-mesenchymal transition 
(EMT) that are important for cell motility and 
metastasis. Results of this study indicate that lncRNA 
SRA is an important feature directly related to disease 
progression, death, and recurrence as well as 
endometrial cancer tumor growth, metastasis, EMT, 
and multiple regulators. These findings indicate that 
SRA may represent a novel biomarker for predicting 
recurrence and prognosis. It can serve as a promising 
therapeutic target in endometrial cancer. 
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